Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Wellington Management Group reports 10.85% passive stake in PTC Therapeutics  08:14
05/08/20
05/08
08:14
05/08/20
08:14
PTCT

PTC Therapeutics

$46.94 /

-1.23 (-2.55%)

 
ShowHide Related Items >><<
PTCT PTC Therapeutics
$46.94 /

-1.23 (-2.55%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
Hot Stocks
PTC Therapeutics to acquire Censa Pharmaceuticals » 16:53
05/06/20
05/06
16:53
05/06/20
16:53
PTCT

PTC Therapeutics

$48.17 /

-1.09 (-2.21%)

PTC Therapeutics…

PTC Therapeutics announced that it has entered into an agreement to acquire Censa Pharmaceuticals, a biopharmaceutical company focused on the development of CNSA-001, a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria and other diseases associated with defects in the tetrahydrobiopterin biochemical pathways diagnosed at birth. The transaction was approved by the Boards of both companies. The transaction is expected to close in the second quarter, pending successful fulfillment of closing conditions. PTC is not obligated to give full time employment to any Censa personnel or acquire any additional facilities in connection with the closing. Under the terms of the merger agreement, PTC will pay an upfront consideration of approximately $10M in cash and up to 850,000 shares of PTC common stock. In addition to the upfront payments, potential future consideration includes $217.5M in development and regulatory milestones for the two most advanced programs and receipt of a priority review voucher, including $30M to be paid in either cash or PTC common stock at our option for completing the enrollment of a Phase 3 clinical trial for CNSA-001 for PKU, $109M in development and regulatory milestones for each additional indication of CNSA-001, net sales milestones up to an aggregate amount of $160M and a contingent value payment of a percentage of annual net sales ranging from single to low double digits.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$48.17 /

-1.09 (-2.21%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
Earnings
PTC Therapeutics reports Q1 EPS ($1.81), consensus ($1.32) » 16:07
04/30/20
04/30
16:07
04/30/20
16:07
PTCT

PTC Therapeutics

$51.39 /

-2.14 (-4.00%)

Reports Q1 revenue…

Reports Q1 revenue $68.3M, consensus $81.94M. "PTC continued to execute on our strategic priorities including the development and commercial fronts in the first quarter highlighted by DMD franchise revenue growth and strong risdiplam results," said CEO Stuart Peltz. "The breadth of positive clinical risdiplam data reinforces the global commercial competitive profile of this therapy, which has the potential to be the first and only at-home SMA treatment, a critical advantage in the COVID-19 environment. We look forward to a number of potential value-creating catalysts including the risdiplam PDUFA date, and multiple clinical milestones in the upcoming months."

ShowHide Related Items >><<
PTCT PTC Therapeutics
$51.39 /

-2.14 (-4.00%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
Periodicals
PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says » 11:57
04/29/20
04/29
11:57
04/29/20
11:57
BIIB

Biogen

$311.64 /

+6.69 (+2.19%)

, PTCT

PTC Therapeutics

$53.28 /

-0.52 (-0.97%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

After Roche (RHHBY) and…

After Roche (RHHBY) and PTC Therapeutics (PTCT) disclosed yesterday that risdiplam led to a 93% one-year survival rate among infants with the most severe form of spinal muscular atrophy, or SMA, STAT News' Damian Garde said the trial results may suggest "diminishing returns in the future" for Biogen's (BIIB) Spinraza, which he identifies as "among the few bright spots in a trying few years for the company." Reference Link

ShowHide Related Items >><<
BIIB Biogen
$311.64 /

+6.69 (+2.19%)

04/23/20
Fly Intel: Top five analyst downgrades
04/23/20 Oppenheimer
Biogen price target lowered to $365 from $390 at Oppenheimer
04/23/20 Raymond James
Biogen downgraded to Underperform from Market Perform at Raymond James
04/23/20 Jefferies
Biogen may lack catalysts until more aducanumab clarity, says Jefferies
PTCT PTC Therapeutics
$53.28 /

-0.52 (-0.97%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
RHHBY Roche
$0.00 /

+ (+0.00%)

04/28/20 UBS
Roche price target raised to CHF 380 from CHF 350 at UBS
04/28/20 Morgan Stanley
Roche price target raised to CHF 370 from CHF 360 at Morgan Stanley
04/23/20 JPMorgan
Roche price target raised to CHF 400 from CHF 375 at JPMorgan
04/16/20 BTIG
Arcus Biosciences price target raised to $34 from $20 at BTIG
Hot Stocks
PTC Therapeutics announces results from part 2 of pivotal FIREFISH study » 06:23
04/28/20
04/28
06:23
04/28/20
06:23
PTCT

PTC Therapeutics

$53.26 /

+0.21 (+0.40%)

PTC Therapeutics…

PTC Therapeutics announced positive results from part 2 of the pivotal FIREFISH study evaluating risdiplam in infants with type 1 spinal muscular atrophy. The global study met its primary endpoint of infants sitting without support for five seconds by month 12, as assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition, or BSID-III. Type 1 SMA babies do not achieve this milestone without therapy. Substantial results were demonstrated across multiple secondary and exploratory endpoints, as infants in the study achieved milestones not seen in natural history. In addition to being able to sit without support, infants were able to maintain upright head control, roll to the side, and stand without support after 12 months of treatment. At 12 months, 95% infants maintained the ability to swallow and 89% were able to feed orally. No new safety signals were identified in part 2 of the study.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$53.26 /

+0.21 (+0.40%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
Over a month ago
Hot Stocks
ClearPoint Neuro appoints Matthew Klein to board of directors » 08:16
04/17/20
04/17
08:16
04/17/20
08:16
CLPT

ClearPoint Neuro

$3.58 /

-0.26 (-6.77%)

, PTCT

PTC Therapeutics

$47.45 /

+0.93 (+2.00%)

ClearPoint Neuro (CLPT)…

ClearPoint Neuro (CLPT) announced that Matthew Klein, MD, MS, FACS, has been appointed to ClearPoint Neuro's Board of Directors effective immediately. Dr. Klein, chief development officer of PTC Therapeutics, Inc. (PTCT), is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon. He succeeds Marcio Souza, who joined ClearPoint Neuro's Board as PTC's representative in connection with PTC's May 2019 equity investment in ClearPoint Neuro. Souza, who resigned from his position as PTC's COO, as was announced by PTC on March 16, 2020, will remain on ClearPoint Neuro's Board as an independent member.

ShowHide Related Items >><<
CLPT ClearPoint Neuro
$3.58 /

-0.26 (-6.77%)

03/12/20 Brookline
ClearPoint Neuro initiated with a Buy at Brookline
PTCT PTC Therapeutics
$47.45 /

+0.93 (+2.00%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
Hot Stocks
PTC Therapeutics makes two new leadership appointments » 08:03
04/17/20
04/17
08:03
04/17/20
08:03
PTCT

PTC Therapeutics

$47.45 /

+0.93 (+2.00%)

PTC Therapeutics…

PTC Therapeutics appointed Matthew Klein to Chief Development Officer and Eric Pauwels to Chief Business Officer. Klein will be responsible for the development of clinical stage programs. As Chief Business Officer, Pauwels will be responsible for customer facing activities with health care providers, patients and payers. Klein joined PTC last year as Global Head of Gene & Mitochondrial Therapies after serving as CEO and CMO of BioElectron Technology. Pauwels joined PTC in 2015 as Senior VP and General Manager of the Americas, overseeing commercial strategy and market access.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$47.45 /

+0.93 (+2.00%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
Conference/Events
PTC Therapeutics participates in a conference call with SunTrust » 11:25
04/15/20
04/15
11:25
04/15/20
11:25
PTCT

PTC Therapeutics

$46.71 /

-0.82 (-1.73%)

Biotech Analyst…

Biotech Analyst Karnauskas holds a conference call with CEO Peltz and CFO Hill on April 15 at 12 pm hosted by SunTrust.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$46.71 /

-0.82 (-1.73%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
Conference/Events
PTC Therapeutics participates in a conference call with SunTrust » 04:55
04/15/20
04/15
04:55
04/15/20
04:55
PTCT

PTC Therapeutics

$47.53 /

+2.74 (+6.12%)

Biotech Analyst…

Biotech Analyst Karnauskas holds a conference call with CEO Peltz and CFO Hill on April 15 at 12 pm hosted by SunTrust.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$47.53 /

+2.74 (+6.12%)

04/09/20 Citi
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey
04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
Upgrade
Citi upgrades PTC Therapeutics to Buy on favorable doctor survey » 06:01
04/09/20
04/09
06:01
04/09/20
06:01
PTCT

PTC Therapeutics

$44.18 /

+1.45 (+3.39%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty upgraded PTC Therapeutics to Buy from Neutral with a price target of $67, down from $71. The analyst's doctor survey results suggest that clinicians have a favorable view on Risdiplam in spinal muscular atrophy, particularly for patients older than two years of age. The survey results suggest that Risdiplam could be the preferred product over Spinraza for the prevalent population, Beatty tells investors in a research note.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$44.18 /

+1.45 (+3.39%)

04/09/20 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
04/08/20 Cantor Fitzgerald
Cantor still 'positive' about commercial potential for PTC's risdiplam
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.